Get the latest Science News and Discoveries

New experimental drug cagrilintide (AM833), when combined with emaglutide, shows potential for treatment of obesity (The Lancet)

None

Related news:

The Lancet: More nurses lead to fewer patient deaths&readmissions, shorter hospital stays, and savings

The Lancet Infectious Diseases: Non-hospitalised COVID-19 patients have low-risk of serious long-term effects, but report more visits to general practitioner following infection

The Lancet Rheumatology: Largest study to date confirms non-steroidal anti-inflammatory medications do not result in worse COVID-19 outcomes

« C.D.C Confirms More Cases of Rare Blood Clot Disorder Linked to J.&J. Vaccine

Study finds that obesity drug semaglutide supresses appetite, food cravings and energy intake »